a) Cohort structured by **Dabrafenib** pairwise response similarity

lot
- 0
- 1
- 2_or_more

driver mutation
- BAP1
- BRAF_V600x
- BRAF_non_V600x
- GNA11
- GNAQ
- NF1
- NRAS
- wt

b) Treatment strength

c) Predicted responses of marker pERK

d) EMD pERK evaluations
Conditional CellOT vs other models

e) Predicted Dabrafenib pERK marginals of holdout samples

Model
- CellOT (conditional)
- CellOT
- treated
- control

BRAF v600 positive

madegod, mahobam, malylej, mapoxub, meducin, medycar, mihifib

milabyl, modudol, movazyq, mufacik, mujagif, mukagox, mynesyb

BRAF v600 negative

macegej, majefev, mecuguh, mecygyr, mehufef, mehylob, mekakyd

melipit, mimanar, mimuvyf, mipynap, mobicun, moceloj, mogylip

mololyb, mubibit, mucadop, mugakol, mumifad, myjadaf, myjilas